Fundación Gecp

This study is for people with non-small cell lung cancer who had surgery but still had cancer cells left behind. It tests whether adding two drugs (sacituzumab and zimberelimab) after surgery can help keep the cancer from returning. About 129 participants will be split into three…

This study tests a drug called sotorasib in people with stage III lung cancer that has a specific genetic change (KRAS G12C) and cannot be treated with standard chemo and radiation together. About 19 participants will receive the drug to see if it can stop the cancer from growing…

This study tests a treatment plan for people with stage III lung cancer. First, patients get three rounds of chemotherapy plus the immunotherapy drug atezolizumab. Then, depending on how the tumor responds, they either have surgery followed by more atezolizumab, or radiation ther…

This study tests a drug called tarlatamab as a maintenance treatment for people with limited-stage small cell lung cancer who cannot receive standard chemo-radiotherapy together. About 37 participants will receive tarlatamab infusions after initial treatment to see if it delays c…

This study looks at how the immune system responds to immunotherapy after chemo-radiation in people with stage III non-small cell lung cancer that cannot be removed by surgery. Researchers will review medical records of 50 patients to see how long they live or stay cancer-free. N…